Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SYS6043 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on SYS6043, a putative antibody-drug conjugate (ADC) targeting CD276 (B7-H3) (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SYS6043 | SYS-6043|SYS 6043 | CD276 Antibody 22 | Limited information is currently available on SYS6043, a putative antibody-drug conjugate (ADC) targeting CD276 (B7-H3) (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07424547 | Phase Ib/II | SYS6043 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |